Management | Medibuddy
20th June 2026

Management

Managing pre-eclampsia requires attention to the following critical considerations: 

  • Monitoring
  • Delivery: date and method
  • Controlling blood pressure
  • Controlling seizures
  • Postnatal fluid management

Important considerations

  • Antihypertensive treatment: choice should be based on pre-existing treatment, possible side effects, maternal vs foetal risk, and the woman’s preference. Combination therapy may be required.
  • Corticosteroids (e.g. betamethasone) to promote foetal lung maturation, as indicated
  • Magnesium sulphate if planned early delivery. It is the treatment of choice for eclampsia. Monitor for signs of magnesium toxicity (e.g. respiratory depression and loss of reflexes); calcium gluconate may be used as a reversal agent.
  • Delivery: the definitive management of pre-eclampsia, however it may take a few days to resolve completely. Indications for planned early delivery < 37 weeks may include the following:
    • Inability to control maternal BP despite ≥ 3 classes of antihypertensives
    • Maternal pulse oximetry < 90%
    • Progressive deterioration in blood results
    • Ongoing neurological features, e.g. severe intractable headache, repeated visual scotomata
    • Placental abruption
    • Reversed end-diastolic flow in umbilical artery doppler velocimetry, a non-reassuring CTG, or stillbirth

Table 9. Management of pre-eclampsia

Management Hypertension Severe hypertension
Admit to hospital Admit to hospital if clinical concerns for maternal or foetal wellbeing, e.g. impending eclampsia, pulmonary oedema or suspected foetal compromise
Admit to hospital.
If BP falls < 160/110 mmHg, manage as for hypertension
Risk prediction models like fullPIERS or PREP-S have been validated and can be used alongside a comprehensive clinical assessment to help guide decisions about admission and thresholds for intervention
BP monitoring At least every 48 hours (more frequently if an inpatient)
Every 15-30 mins until BP < 160/100 mmHg, then ≥ 4 times daily while an inpatient
Urine protein levels Only repeat if clinically indicated, e.g. if new symptoms or signs develop, or if there is uncertainty over diagnosis
Blood tests FBC, LFTs and renal function 2x / week FBC, LFTs and renal function 3x / week
Foetal assessment Foetal heart auscultation at every antenatal appointment
Foetal US at diagnosis – if normal, repeat every 2 weeks
CTG at diagnosis, then only if clinically indicated
Antihypertensive medication 1st line: Labetalol
2nd line: Nifedipine
3rd line: Methyldopa
Offer if BP > 140/90 mmHg
Target BP: ≤ 135/85 mmHg
Offer to all women
Target BP: ≤ 135/85 mmHg
Timing of delivery < 34 weeks: continue surveillance unless there are indications for planned early birth. Offer IV magnesium sulphate and corticosteroids
34-36+⁶ weeks: continue surveillance unless there are indications for planned early birth. Consider corticosteroids
≥ 37 weeks: initiate birth within 24-48 hours

fullPIERS, Pre-eclampsia Integrated Estimate of RiSk; PREP-S, Prediction of complications in early-onset pre-eclampsia (using a survival model).

Postnatal investigation, monitoring and treatment

  • Measure BP at least once between day 3 and 5 after birth, then on alternate days until normal, if BP was abnormal
  • Continue antihypertensive treatment if required. Start treatment if BP ≥ 150/100 mmHg and they were not treated during pregnancy. Reduce treatment dosages if BP falls < 130/80 mmHg
  • Follow-up with GP or specialist 6-8 weeks after birth, or 2 weeks after transfer to community care for women who remain on antihypertensive treatment
  • The main risk to the mother in this period is fluid overload; therefore, fluid management is crucial. NICE guidelines fluid restriction to 80 ml/hour
Mobile app screenshots

Take your subscriptions with you

Our mobile app allows you to access your interview and exam question banks wherever you are.